Recent Updates
Recently added Catalysts
ENVB Positive Sentiment Score: 60/100

New antidepressants: Tackling treatment resistant depression [LaBiotech]

Key Takeaway: The article discusses the global prevalence of depression, affecting about 5% of adults. It highlights various depressive disorders, including major depressive disorder and seasonal affective disorder, which can severely impact individuals' lives. The focus is on the development of new antidepressants aimed at treating those who are resistant to current treatments.
Price reaction · baseline $2.04 (2026-05-19T19:18:00.000Z) · hit during market hours · 1 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+3.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • New antidepressants are being developed to address treatment-resistant depression.
  • Increased awareness of depression's impact on adults worldwide.
  • Potential for improved quality of life for patients with depressive disorders.

Full Press Release Details

Depression is thought to affect approximately 5% of adults worldwide. It encompasses several different depressive disorders, including major depressive disorder, seasonal affective disorder, and persistent depressive disorder, all of which can bring enormous difficulty to people’s lives, resulting in symptoms like poor concentration, hopelessness about the future, feeling tired or low in energy, and suicidal thoughts.
Full Article >>

Frequently Asked Questions

What percentage of adults are affected by depression?

Approximately 5% of adults worldwide are affected by depression.

What are some types of depressive disorders?

Types include major depressive disorder, seasonal affective disorder, and persistent depressive disorder.

What symptoms are associated with depression?

Symptoms can include poor concentration, hopelessness, low energy, and suicidal thoughts.

What is the focus of new antidepressant development?

The focus is on treating individuals with treatment-resistant depression.

Last updated: May 19, 2026